| |
London, United Kingdom, 01/14/2009 – The introduction of novel vaccines for diseases with high burden and continuous investments aimed at boosting production capacity is driving the growth of this previously unattractive market.
New analysis from Frost & Sullivan (pharma.frost.com), European Vaccines Market, finds that the market earned revenues of $4.50 billion in 2007 and estimates this to reach $9.85 billion in 2014.
“Health authorities are prepared to spend on prevention, rather than witness expenditures on vaccine-preventable diseases spiral out of control,” notes Frost & Sullivan Research Analyst John Paul. “The growing support for vaccinations from physicians and paediatricians has been fundamental to the growth of the vaccines market.”
The market has shown remarkable growth in recent years as a result of the introduction of vaccines in untapped disease segments. Governments’ acceptance and reimbursement of such efficient, albeit expensive, vaccines has encouraged market participants to increase investments in R&D and develop innovative and differentiated products. Innovation in technology has enabled manufacturers to move ahead into promising areas like therapeutic vaccines where the potential for growth is unlimited.
However, Europe is already at a disadvantage because of the ban on direct-to-consumer marketing. Uptake levels in Europe remain slower than in the US market. In addition to the inherent challenges in vaccine manufacture and R&D, market participants also have to deal with government policies, perceptions and awareness levels that diverge widely across Europe.
“A clear comprehension about the dynamics in various regions is important to predict demand and alter business strategies accordingly,” explains Paul. “Predicting and meeting demand is one of the most challenging factors in the vaccines industry. Efficiency in manufacturing and distribution has to be achieved in order to offset limited production capacities and low profit margins.”
Keeping abreast of epidemiological trends and government policies, coupled with efforts to boost physician and public awareness, will be crucial. In the context of R&D, the identification of the disease areas to be targeted, through a vaccine or a combination, is important because market penetration and revenue generation are largely dependent upon these factors in various regions.
“Vaccine manufacturers should be able to identify key market dynamics, promote efficiency of operation and support public perception while adapting and implementing lean principles and innovative marketing strategies,” advises Paul. “Streamlining investments into R&D of adjuvant technologies, therapeutic and DNA vaccines could enable realisation of significant potential in these areas.”
If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants with an overview of the European vaccines market, then send an email to Katja Feick, Corporate Communications, at katja.feick[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by email.
European Vaccines Market is part of the Pharmaceuticals & Biotechnology Growth Partnership Services Programme, which also includes research in the following markets: European Therapeutic Monoclonal Antibody Markets, European Human Growth Hormones Market, European Pharma/biotech Contract Manufacturing Markets: A Strategic Outlook and European Drug Delivery Markets - Opportunity Analysis. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.
Frost & Sullivan (frost.com), the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents.
European Vaccines Market
M276
|
katja.feick[.]frost.com 
